Echinacea for Colds: What the Evidence Says

What is echinacea?

Echinacea is a group of flowering plants used in cold remedies. Supplements commonly contain Echinacea purpurea, E. angustifolia or E. pallida, using roots, above-ground parts or a combination. Products include pressed juices, tinctures, tablets and dry extracts.

The species, plant part and whether the product contains powder or extract identify what “Echinacea 500 mg” actually describes.

Historical uses and today's extracts

The USDA's account of Echinacea angustifolia^[1] describes different practices among Indigenous communities of the Great Plains. Kiowa people chewed its root for coughs and sore throats. Dakota and other named communities used the root for toothache and washes for burn pain; Omaha people applied smashed-root poultices to the arms and hands.

Modern cold research partly overlaps with the older respiratory uses, but often tests E. purpurea above-ground material or two-species tablets.

Why do people take echinacea?

Claimed benefit	Dose / form studied	Research verdict	Evidence strength
Reduce cold symptoms over a season	Fresh E. purpurea herb-and-root drops over four months	Fewer total cold days in one adult trial; the difference in the number of episodes was not statistically clear.	Limited
Shorten a cold after symptoms start	Different preparations and treatment schedules	The Cochrane review describes inconsistent findings across products.	Review pending
Prevent respiratory illness in children	Echinaforce Junior, 1,200 mg/day for two two-month courses	One trial recorded fewer cold days and antibiotic-treated children than vitamin C.	Review pending
Relieve anxiety	EP107 E. angustifolia extract, 40 or 80 mg/day for six weeks	Anxiety improved no more than with placebo; some secondary mood measures favored the extract.	Review pending

“Immune support” is too broad to tell you what to expect. Fewer colds, fewer sick days and feeling less unwell are measurable but different goals.

When to ask a doctor before taking it

Ask before giving echinacea to a child, particularly one with allergies. NCCIH reports rashes in a children’s trial. If you take prescription medicines, particularly immune-suppressing treatment, have a pharmacist check your medicine list and proposed extract; several interaction concerns remain theoretical or conflicting rather than proven for every product.

What the different preparations tell you on the label

Preparation	Label information	What it tells you
Pressed juice	Species, plant part and amount of juice	Fresh above-ground parts differ from root extracts.
Dry extract or tablet	Actual extract mass; weight of starting root/herb; solvent and extraction ratio	Starting-root weight is not the weight of extract in the tablet.
Tincture	Concentration, serving in mL and alcohol content	Drops and milligrams are not interchangeable units.
Combination cold remedy	All ingredients and individual amounts	A combination result cannot be assigned to echinacea alone.

An extract ratio describes how much starting plant material was used to make the extract; the solvent describes the extraction liquid. These details identify how a preparation was made. They do not, by themselves, show that one extract works better than another.

Third-party identity and contaminant testing can improve confidence in composition.

Drawbacks and side effects

Potential drawback	When/who it affects	Research evidence	Practical implication
Nausea or abdominal pain	Oral supplement users	Commonly described tolerability effects	Stop if symptoms outweigh any perceived benefit.
Allergy, occasionally severe	Susceptible adults and children	Clinical reports and trial rashes	Seek urgent help for swelling or breathing difficulty.
Uncertain interaction	Some medicines processed by the liver; immunosuppressants	Conflicting or theoretical evidence	Review the exact preparation and medicine list.
Pregnancy/breastfeeding uncertainty	Women considering medicinal use	Limited preparation-specific data	Discuss medicinal use with the prenatal clinician.

Can echinacea prevent a cold?

Prevention and treatment answer different questions. In prevention trials, people take a preparation before illness; treatment trials begin after symptoms. The 2014 Cochrane review^[2] included 24 trials and 4,631 participants. Its abstract reports that none of 12 prevention comparisons showed a statistically clear reduction in people having at least one cold, although an additional analysis combining results from different trials suggested a small benefit. Because species, plant parts and extraction methods differed, the reviewers kept the trials separate in their main analysis.

Fresh herb-and-root drops in adults

In a four-month trial^[3], 755 adults were allocated to Echinaforce drops (379) or placebo (376). At least one contact after enrollment was recorded for 355 and 362 participants respectively; 325 and 348 completed the study. Participants reported at least two colds a year and were mostly young adults. The extract contained 95% fresh E. purpurea above-ground material and 5% root. The schedule was 0.9 mL three times daily, increased to five times daily during a cold.

Researchers counted 672 total cold days with the extract versus 850 with placebo, a statistically significant difference. They counted 149 versus 188 cold episodes, but that difference was not statistically significant. Total cold days combine how often illness occurs with how long it lasts; they are not the number of people who avoided a cold. The higher dose during illness also makes this more than a fixed-dose prevention comparison.

Respiratory symptoms during long-haul travel

A separate trial^[4] randomized 175 adults aged 18–65 before long-haul flights. The tablets combined E. purpurea and E. angustifolia root extracts. Participants took one tablet twice daily, two twice daily around flights, and could use three twice daily when sick. Treatment ran from two weeks before departure to two weeks after return, roughly five to nine weeks altogether.

At return, the median respiratory symptom score was 13 with echinacea versus 26 with placebo, at the study's statistical threshold. The 13-point gap was smaller than the 16.7-point change the authors described as worthwhile to patients. At the later follow-up, fewer participants receiving echinacea fell into the study’s higher-symptom group, even though the median-score comparison was not statistically clear. Headache, sleep and cold sores also showed no clear difference. The survey asked about four weeks of symptoms, rather than counting diagnosed colds. Five randomized participants were omitted from the analysis, and the company supplying the product also supplied the randomization sequence.

Prevention in children

In a Swiss trial^[5], children aged 4–12 took Echinaforce Junior or vitamin C for two two-month courses separated by a week. Each daily echinacea serving supplied 1,200 mg of fresh E. purpurea extract, 95% above-ground material and 5% root. The comparison was 150 mg/day vitamin C, rather than an inert placebo.

Of 203 children recruited, 201 contributed safety or efficacy data: 103 receiving echinacea and 98 vitamin C. The groups recorded 429 versus 602 total cold days. Six of 103 versus 15 of 98 children received antibiotics, involving 6 versus 24 courses.

The manufacturer funded the trial, and an employee and consultant were authors. Children with actively treated asthma or allergies were excluded. Discuss use in a child with their clinician.

Can it shorten an ongoing cold?

The Cochrane review's abstract reports that only two of six treatment trials with duration data found a statistically significant benefit. Its JAMA synopsis^[6] describes the four lower-risk trials as finding no clear shortening, with positive findings in two trials whose risk of bias was higher or unclear. The synopsis summarizes the same review, rather than providing a separate set of trials.

Those inconsistent treatment findings leave the effect on an established cold uncertain.

What about anxiety?

A particular E. angustifolia extract, EP107, has also been studied for anxiety. In a six-week trial^[7], 108 adults with mild-to-moderately severe anxiety were randomized to 40 mg/day, 80 mg/day or placebo; the published abstract reports data from 104. Neither dose improved the main anxiety score more than placebo. Both doses favored some secondary measures of positive and negative feelings and emotional wellbeing.

The European Food Safety Authority's 2026 assessment^[8] identifies the extract in this same six-week trial as Anxiofit-1, a standardized E. angustifolia root extract. It assessed that trial alongside other Anxiofit-1 studies. Two seven-day trials at 80 mg/day favored the extract for state anxiety, meaning how anxious someone feels at the time, but not trait anxiety, their usual tendency to feel anxious. The six-week trial used a different anxiety questionnaire, CUXOS, and found no advantage over placebo.

EFSA also examined a small trial in patients diagnosed with generalized anxiety disorder, published in 2025. Groups differed substantially at the start; some differences favored the extract during treatment, but not at the final six-week visit. EFSA concluded that this trial could not establish an independent treatment effect. It found insufficient evidence that the extract reduces mild anxiety as a risk factor for developing anxiety or depressive disorders.

The bottom line

Some specific echinacea preparations have encouraging cold-prevention findings, but results depend on the preparation, population and outcome measured. Shortening an illness already underway remains uncertain. The anxiety research is mixed: short-term signals coexist with a six-week null result. Species, plant part, extraction method and study purpose matter more than a generic “echinacea” milligram number.

Help us improve this article

Spotted an error or found a source we should consider? Tell us which part of this article needs another look and include a link if you have one. Please leave out personal health details and lab results; we can’t answer individual medical questions.